FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 03:47:32 2024-06-20 pm EDT | ||
| 0.186 EUR | -2.11% |
|
| Current month | -11.43% | ||
| 1 month | -19.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 0.186 | -2.11% |
| 24-06-19 | 0.19 | 0.00% |
| 24-06-18 | 0.19 | +5.56% |
| 24-06-17 | 0.18 | +5.88% |
| 24-06-14 | 0.17 | -1.73% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 03:47 pm EDT
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD33DU |
| ISIN | DE000MD33DU7 |
| Date issued | 2022-03-31 |
| Strike | 584.1 $ |
| Maturity | Unlimited |
| Parity | 572.03 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.48 € |
|---|---|
| Lowest since issue | 0.16 € |
| Spread | 0.001 € |
| Spread % | 0.54% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4
USD
Average target price
463.4
USD
Spread / Average Target
-1.69%
- Stock Market
- Certificates
- Certificat
